Aclidinium bromide vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Azurity Pharmaceuticals and partners
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).
Reported efficacy
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)
Result source: NCT03022097
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Reported efficacy
Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)
Result source: NCT02164513
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.4 vs 0.6−0.1 vs placeboNCT01966107 | 0.9 vs 1.1vs FF/VINCT021645132 other results
|
| Trough FEV1, change | 0.1 vs -0.1+0.2 vs placeboNCT0302209725 other results
| 0.1 vs -0.0vs BUD/FORNCT0234516114 other results
|
| SGRQ total, change | -3.6 vs -1.9−1.8 vs placeboNCT015727927 other results
| -6.6 vs -4.3vs BUD/FORNCT023451613 other results
|
| TDI focal score | 2.9 vs 2.1+0.8 vs placeboNCT030220975 other results
| 2.3 vs 1.7vs BUD/FORNCT023451611 other result
|
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide
- 0.4 vs 0.6−0.1 vs placeboNCT01966107
- fluticasone furoate/umeclidinium/vilanterol
- 0.9 vs 1.1vs FF/VINCT02164513
2 other results
- 0.2 vs 0.3 NCT02345161
- 0.2 vs 0.4 NCT02345161
Trough FEV1, change
- Aclidinium bromide
- 0.1 vs -0.1+0.2 vs placeboNCT03022097
25 other results
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 1.2 vs 1.2 NCT00358436
- 1.2 vs 1.2 NCT00358436
- 0.1 vs -0.0 NCT00891462
- 0.1 vs -0.0 NCT01045161
- 0.1 vs -0.0 NCT01001494
- 0.0 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT00891462
- 0.0 vs -0.0 NCT01045161
- 0.0 vs -0.0 NCT01001494
- 0.1 vs 0.1 NCT02796677
- 0.0 vs -0.1 NCT01572792
- 0.0 vs -0.1 NCT01572792
- 0.1 vs -0.0 NCT00500318
- 0.1 vs -0.0 NCT02153489
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs -0.0vs BUD/FORNCT02345161
14 other results
- 0.1 vs -0.1 NCT02345161
- 0.1 vs 0.1 NCT02729051
- 0.1 vs -0.0 NCT02164513
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs -0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.0 vs -0.0 NCT03478696
- 0.0 vs 0.0 NCT03478683
SGRQ total, change
- Aclidinium bromide
- -3.6 vs -1.9−1.8 vs placeboNCT01572792
7 other results
- -5.5 vs -1.9 NCT01572792
- -8.7 vs -4.7 NCT03022097
- -7.6 vs -4.7 NCT03022097
- -6.6 vs -2.2 NCT01437397
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- fluticasone furoate/umeclidinium/vilanterol
- -6.6 vs -4.3vs BUD/FORNCT02345161
3 other results
- -4.6 vs -1.9 NCT02345161
- -5.5 vs -3.7 NCT02164513
- -5.8 vs -4.9 NCT02729051
TDI focal score
- Aclidinium bromide
- 2.9 vs 2.1+0.8 vs placeboNCT03022097
5 other results
- 2.6 vs 2.1 NCT03022097
- 2.0 vs 0.6 NCT01437397
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- fluticasone furoate/umeclidinium/vilanterol
- 2.3 vs 1.7vs BUD/FORNCT02345161
1 other result
- 1.7 vs 1.4 NCT02345161
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Aclidinium bromide: 5 of 5 rows · fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide Rows use multiple source trials | fluticasone furoate/umeclidinium/vilanterol Rows use multiple source trials |
|---|---|---|
| Time to First Moderate or Severe Exacerbation time to event · months | NA vs NA placebo months @ 52wk200 μg once-dailya,b,c NCT00358436 · Phase 3 · monotherapy | NA vs NA FF/VI + UMEC months100/62.5/25a,b,c NCT02729051 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 14.2%200 μg Once-dailyd NCT00363896 · Phase 3 · monotherapy show 34 more results25.7%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.1%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 12.6%400µg NCT00891462 · Phase 3 17.8%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 6.3%400 μg Bid NCT01001494 · Phase 3 8.7%200 μg Bid NCT01001494 · Phase 3 44.3% NCT01966107 · Phase 4 4.4%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 18.3%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 18.3%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 10.5%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 2.9%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 44.7%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 42.6%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 5.8% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 10.5%FF/UMEC/VIe NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 4.9%100/62.5/25 µg NCT02345161 · Phase 3 6.1% NCT04923347 · Phase 4 · registry result, not featured evidence 9.5% NCT05535972 · Phase 4 · registry result, not featured evidence 3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 4.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.6%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 3.6%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.8%200 μg Once-dailyd NCT00363896 · Phase 3 · monotherapy show 34 more results4.8%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 1.5%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 3.7%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 1.5%400 μg Bid NCT01001494 · Phase 3 2.9%200 μg Bid NCT01001494 · Phase 3 — NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.5%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6.5%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 2.6%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 6.8%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 7.1%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 3.5% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 3.9%FF/UMEC/VIe NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 1.8%100/62.5/25 µg NCT02345161 · Phase 3 — NCT04923347 · Phase 4 · registry result, not featured evidence 1.3% NCT05535972 · Phase 4 · registry result, not featured evidence 0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 1.5%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 0.3%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 1.4%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 8%200 μg Once-dailyd NCT00363896 · Phase 3 · monotherapy show 34 more results10.3%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.9%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.4%400 μg Bid NCT01120093 · Phase 2 1.4%200 μg Bid NCT01120093 · Phase 2 0%100 μg Bid NCT01120093 · Phase 2 3.2%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 4.5%400 μg NCT01045161 · Phase 3 9.5%400 μg NCT01045161 · Phase 3 6%200 μg NCT01045161 · Phase 3 13%200 μg to 400 μg NCT01045161 · Phase 3 5.6%400 μg Bid NCT01001494 · Phase 3 4.3%200 μg Bid NCT01001494 · Phase 3 22.8% NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence 0%400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 7.7%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.9%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 5.7%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 5.4%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 4.7%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence 0%400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 10%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 9.3%200µg NCT01044459 · Phase 3 · registry result, not featured evidence 12.3%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.2%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 14%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.9%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 2.3% NCT00500318 · Phase 3 · registry result, not featured evidence 0%400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | —FF/UMEC/VIe NCT02164513 · Phase 3 show 9 more results21.6%100/62.5/25 NCT02164513 · Phase 3 6.7%100/62.5/25 µg NCT02345161 · Phase 3 0.4% NCT04923347 · Phase 4 · registry result, not featured evidence 4.1% NCT05535972 · Phase 4 · registry result, not featured evidence 7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 3.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.4%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 8%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 200 μg Once-dailyd nasopharyngitis 16.3% (placebo 14.4%) headache 11.3% (placebo 12.5%) back pain 4.8% (placebo 4.6%) NCT00363896 · Phase 3 · monotherapy show 34 more results200 μg once-daily headache 14.2% (placebo 12.7%) nasopharyngitis 12.7% (placebo 11.3%) upper respiratory tract infection 10.8% (placebo 9.8%) NCT00358436 · Phase 3 · monotherapy 400 μg upper respiratory tract infection 9.4% (placebo 8.9%) chronic obstructive pulmonary disease 7.9% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400 μg copd exacerbation 13% (placebo 11.5%) upper respiratory tract infection 1.7% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 400 μg copd exacerbation 27.9% (placebo 11.5%) upper respiratory tract infection 5.4% (placebo 0.5%) nasopharyngitis 4.1% (placebo 0%) NCT01045161 · Phase 3 200 μg copd exacerbation 8.7% (placebo 11.5%) upper respiratory tract infection 1.6% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 200 μg to 400 μg copd exacerbation 22.7% (placebo 11.5%) nasopharyngitis 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 0.5%) NCT01045161 · Phase 3 400 μg Bid chronic obstructivce pulmonary disease 14.1% (placebo 20.5%) headache 12.3% (placebo 8.1%) nasopharyngitis 11.2% (placebo 8.4%) NCT01001494 · Phase 3 200 μg Bid chronic obstructivce pulmonary disease 15.9% (placebo 20.5%) nasopharyngitis 11.6% (placebo 8.4%) headache 10.8% (placebo 8.1%) NCT01001494 · Phase 3 urinary tract infection 5% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 5.6%) viral upper respiratory tract infection 4.4% (placebo 3.7%) NCT01966107 · Phase 4 400 μg headache 5.2% (placebo 9.7%) nasopharyngitis 3% (placebo 6.7%) NCT02375724 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 20.3% (placebo 15.8%) urinary tract infection 8.2% (placebo 5.5%) nasopharyngitis 7.7% (placebo 4.8%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 22.1% (placebo 15.8%) nasopharyngitis 6.9% (placebo 4.8%) urinary tract infection 6.4% (placebo 5.5%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400 μg BID nasopharyngitis 6.3% (placebo 3.7%) NCT01471171 · Phase 3 · registry result, not featured evidence 400 µg BID nasopharyngitis 6.4% (placebo 2.4%) headache 3.5% (placebo 4.7%) NCT01462929 · Phase 3 · registry result, not featured evidence 400µg chronic obstructive pulmonary disease 19.9% NCT01044459 · Phase 3 · registry result, not featured evidence 200µg chronic obstructive pulmonary disease 19.3% NCT01044459 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 22.6% nasopharyngitis 9.4% urinary tract infection 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 30.4% contusion 10.9% cough 8.7% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 24.7% nasopharyngitis 8.6% back pain 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 36.4% sinusitis 11.4% upper respiratory tract infection 11.4% NCT00970268 · Phase 3 · registry result, not featured evidence cough 5.8% (placebo 3.2%) headache 5.8% (placebo 7.4%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT00500318 · Phase 3 · registry result, not featured evidence 400 μg Bid diarrhoea 6.9% (placebo 0%) chronic obstructive pulmonary disease 0% (placebo 10%) NCT00868231 · Phase 2 · registry result, not featured evidence | 100/62.5/25e viral upper respiratory tract infection 12.5% upper respiratory tract infection 7.2% headache 5.6% NCT02164513 · Phase 3 show 8 more resultsdysphonia 0.4% abdominal discomfort 0.2% abdominal pain upper 0.2% NCT05535972 · Phase 4 · registry result, not featured evidence 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI dyspnoea 2.1% NCT03467425 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 4.5% nasopharyngitis 4% NCT03474081 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 3.6% nasopharyngitis 1.9% NCT03478696 · Phase 4 · registry result, not featured evidence 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for 31 of these studies.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide
show 1 more result
show 3 more results
show 8 more results
show 8 more results
show 4 more results
show 5 more results
show 5 more results
show 3 more results
show 3 more results
show 1 more result
+ 25 further endpoints in the CSV export.
fluticasone furoate/umeclidinium/vilanterol
show 1 more result
show 17 more results
show 1 more result
show 1 more result
show 5 more results
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape